Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, LiquidiaInvestors Business Daily • 06/10/25
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial HypertensionPRNewsWire • 06/10/25
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN StudyPRNewsWire • 05/21/25
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and ProspectsZacks Investment Research • 05/13/25
Insmed Reports First-Quarter 2025 Financial Results and Provides Business UpdatePRNewsWire • 05/08/25
Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028PRNewsWire • 04/24/25
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with BronchiectasisPRNewsWire • 04/23/25
Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025PRNewsWire • 04/23/25
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International ConferencePRNewsWire • 03/25/25
International Markets and Insmed (INSM): A Deep Dive for InvestorsZacks Investment Research • 02/24/25
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with BronchiectasisPRNewsWire • 02/24/25
Insmed's Q4 Loss Wider Than Expected, Sales In Line With EstimatesZacks Investment Research • 02/21/25